罗氟司特
医学
安慰剂
内科学
毒蕈碱拮抗剂
皮质类固醇
支气管扩张剂
随机对照试验
慢性阻塞性肺病
不利影响
临床终点
慢性支气管炎
麻醉
哮喘
敌手
替代医学
受体
病理
作者
Fernando J. Martínez,Klaus F. Rabe,Sanjay Sethi,Emílio Pizzichini,Andrew McIvor,Antonio Anzueto,Vijay Kumar Thyagarajan Alagappan,Shahid Siddiqui,Ludmyla Rekeda,Christopher J. Miller,Sofia Zetterstrand,Colin Reisner,Stephen I. Rennard
标识
DOI:10.1164/rccm.201607-1349oc
摘要
Rationale: Moderate and severe exacerbations are incompletely prevented by maximal inhalation therapy in patients with severe chronic obstructive pulmonary disease.Objectives: To determine whether roflumilast reduces moderate and/or severe chronic obstructive pulmonary disease exacerbations in patients at risk for exacerbations despite treatment with inhaled corticosteroid/long-acting β2-agonist with or without a long-acting muscarinic antagonist (LAMA).Methods: In this 52-week, phase 4, double-blind, placebo-controlled RE2SPOND (Roflumilast Effect on Exacerbations in Patients on Dual [LABA/ICS] Therapy) trial (NCT01443845), participants aged 40 years or older with severe/very severe chronic obstructive pulmonary disease, chronic bronchitis, two or more exacerbations and/or hospitalizations in the previous year, and receiving inhaled corticosteroid/long-acting β2-agonist with or without LAMA daily for 3 or more months were equally randomized to once-daily roflumilast, 500 μg (n = 1,178), or placebo (n = 1,176). Stratification was based on LAMA use.Measurements and Main Results: Although rate of moderate or severe exacerbations per patient per year (primary endpoint) was reduced by 8.5% with roflumilast versus placebo, the between-group difference was not statistically significant (rate ratio, 0.92; 95% confidence interval, 0.81–1.04; P = 0.163). However, roflumilast improved lung function, and in a post hoc analysis roflumilast significantly reduced the rate of moderate or severe exacerbations in participants with a history of more than three exacerbations and/or one or more hospitalizations in the prior year. Adverse event–related discontinuations occurred in 11.7% roflumilast-treated and 5.4% placebo-treated participants. Deaths occurred in 2.5% roflumilast and 2.1% placebo participants.Conclusions: Roflumilast failed to statistically significantly reduce moderate and/or severe exacerbations in the overall population. Roflumilast improved lung function and reduced exacerbations in participants with frequent exacerbations and/or hospitalization history. The safety profile of roflumilast was consistent with that of previous studies.Clinical trial registered with www.clinicaltrials.gov (NCT01443845).
科研通智能强力驱动
Strongly Powered by AbleSci AI